approved glp 1 agonists America's Poison Centers New GLP-1 Guidelines for Type

GLP-1 Drugs present a promising avenue for intervention: Overlapping risk factors: Given the shared risk factors between diabetes and liver disease, the diabetic drug Ozempic is projected to become the second-highest-grossing treatment for NAFLD and NASH by 2028

Investigating local administration through phase 1 safety and pharmacokinetic trials is a critical first step to bypass the BRB and maximize retinal tissue exposure while minimizing systemic side effects

Girish PJ, Abdelmalak BB, Weigal WA, et al

Complementary analyses using a Fine and Gray model and separate application of a cause specific hazard model with time varying inverse probability-of-death censoring weights yielded consistent results (supplementary figure S7)

Orforglipron alone could add hundreds of millions of addressable patients globally

28 (Fig